What Scheriproct Neo Treats: Main Uses and Benefits

Scheriproct Neo is commonly used in contexts where short-term symptomatic assistance is needed to address acute flare-ups. It is considered relevant for easing symptoms related to inflammatory or irritative states of the anal region.

Acute Symptom Management

The medication is commonly used across conditions presenting with acute episodes of anorectal inflammatory conditions, such as hemorrhoids (piles) and proctitis. It is considered relevant for easing symptom clusters that may become intense or disruptive, including localized swelling, redness, acute pain, tenderness, and severe pruritus (itching).

It is relevant in situations where symptoms cluster into patterns requiring supportive management, and is often used during episodes of sudden symptom escalation or in settings requiring temporary symptomatic relief, such as in post-operative care. This support contributes to easing the overall symptom load and may assist with maintaining functional stability.

Quick Fact: Symptom Support for Inflammatory and Painful States

“This medicine is used to provide supportive relief when symptoms interfere with routine activities, helping patients cope more steadily with difficult episodes.”

Regulatory References

1. Health Products Regulatory Authority (HPRA) of Ireland product leaflet

Scheriproct Neo's eligibility profile, as defined by official regulatory documents, establishes specific populations who must not use the medicine and others for whom use is strictly conditional.

Contraindicated Populations

Use is contraindicated for any individual with a known hypersensitivity or allergy to the active ingredients (prednisolone or cinchocaine) or any other components of the formulation. Absolute non-eligibility also applies in the presence of an active untreated infection—specifically viral (such as herpes, shingles, or chickenpox), primary bacterial, fungal, syphilitic, or tuberculous—in the area intended for treatment. Use on traumatised skin is also prohibited.

Restricted and Conditional Use

Age-Related Use Long-term continuous therapy with the topical corticosteroid component must be avoided in infants and small children.

Pregnancy and Lactation Use is generally avoided during the first trimester of pregnancy. For later stages and during breastfeeding, treatment requires a careful review, and prolonged use is explicitly forbidden.

Treatment Duration and Comedication Eligibility is defined by the treatment period, as use should not usually exceed one week. Furthermore, patients receiving co-treatment with certain CYP3A inhibitor medicines are restricted and must be closely monitored or the combination avoided, as per regulatory warnings.

Interactions with other medicines and products — official regulatory information

The interaction profile for Scheriproct Neo is defined by documented metabolic constraints related to the corticosteroid component and by physical compatibility issues with certain non-medicinal products.

Pharmacokinetic Interaction

Property	Details (Based on Official Regulatory Documents)
Interacting Product Class	Potent inhibitors of the Cytochrome P450 3A (CYP3A) enzyme.
Specific Listed Medicine	Cobicistat-containing products.
Interaction-Related Restriction	Co-treatment with these inhibitors is expected to increase the risk of systemic corticosteroid side-effects and is a combination that should be officially avoided.
Procedural Constraint	If the combination is formally judged necessary, patients must be monitored for signs of systemic corticosteroid exposure.

Product–Excipient Compatibility

The excipients contained in both the rectal ointment (e.g., castor oil) and the suppositories (e.g., hard fat) are officially documented to affect other products used in the same area.

• The excipients are stated to reduce the mechanical effectiveness of latex products such as condoms.

This interaction structure establishes two key regulatory constraints: a metabolic restriction that warrants avoidance or monitoring with specific medicines, and a physical constraint related to the reduced reliability of latex barrier products.

How Scheriproct Neo Works

Scheriproct Neo utilizes two distinct mechanistic domains to achieve its physiological effects: Glucocorticoid Receptor Agonism and Voltage-Gated Sodium Channel Blockade.

---

Glucocorticoid Receptor Agonism (Prednisolone Hexanoate)

This domain covers the action of prednisolone hexanoate, a synthetic corticosteroid. It works by binding to intracellular glucocorticoid receptors, which then modulate gene expression to suppress the synthesis and release of pro-inflammatory mediators (like prostaglandins and leukotrienes). This initiates signaling sequences that dampen the local immune response and modify early molecular steps in the inflammatory cascade. The resulting physiological effect is a reduction in capillary dilation, intercellular edema, and inflammatory infiltration, which modulates the activity of dysregulated physiological responses.

---

Neuronal Sodium Channel Blockade (Cinchocaine Hydrochloride)

This domain involves the action of cinchocaine hydrochloride, a local anesthetic. It primarily targets voltage-gated sodium channels on nerve cell membranes, engaging a mechanism that regulates the transmission of afferent signals. By reversibly blocking the influx of sodium ions, it prevents the initiation and conduction of nerve impulses. This effect is a predictable physiological adjustment that establishes a suppressed state within targeted sensory pathways, leading to a temporary and local limitation of afferent sensory signaling.

Instruction Map: How to use Scheriproct Neo

Route of administration	Rectal (used for perianal and intra-rectal application)
Dosing schedule	Ointment: For general use, apply a small quantity (about the size of a pea) twice daily. For severe, acute pain, application may be increased to up to four times on the first day. Suppositories: For general use, insert one suppository daily. For severe, initial symptoms, insert one suppository two to three times daily.
Timing in relation to meals (if applicable)	Not applicable. Administration is contingent on physiological timing (after defaecation).
Preparation requirements (if applicable)	The anal region must be thoroughly cleaned before application. If the suppository is soft, it should be placed in cold water while still wrapped before insertion.
Age-group administration rules	The labeled dosage is defined for adults.
Missed-dose rules	If a dose is forgotten, the patient must not use a double dose to compensate. The patient should continue with the next scheduled dose.
Special procedural conditions	The ointment can be applied externally or internally using the applicator. Protruding lumps should be thickly smeared with ointment and carefully pressed back using a finger.

---

Instruction Classifications (High-Level)

Administration method type	Topical/Rectal
Frequency pattern	Divided daily use (up to four times daily during the acute phase, reducing to once daily or every other day).
Use-context constraints	Time-limited use (must not exceed four weeks total); Condition-dependent timing (post-defaecation).

---

Resulting procedural structure

Step sequence:

• The anal region is thoroughly cleaned and dried, ideally after defaecation.
• The rectal ointment (pea-sized for external use or via applicator for internal use) or suppository is applied according to the prescribed frequency, which begins with a higher rate for severe cases.
• Following symptom improvement, administration frequency must be reduced and continued for at least one week, with the total course not exceeding four weeks.

Connection to the overall use protocol

The use protocol establishes a rectal route of administration with fixed strength formulations. This protocol specifies a high starting frequency for the initial acute phase, followed by a mandated reduction in application frequency and duration that strictly limits the total treatment period, standardizing the product’s delivery method and time constraints.

Research Evidence / Overview of Studies for Scheriproct Neo

Evidence for use in Acute Hemorrhoids (Piles)

Research has explored the use of the combined ingredients—Prednisolone Acetate (a corticosteroid) and Cinchocaine (a local anesthetic)—for contexts related to conditions involving periods of heightened symptoms, specifically acute hemorrhoids. Studies used in research exploring how symptoms change over time and typically involved short-term clinical trials. These research efforts examined outcomes related to physical discomfort, such as measurements of localized pain, pruritus (itching), swelling, and redness.

The findings describe patterns observed in the studies where research monitored outcomes describing episodic or acute changes in patient comfort. The available evidence, which includes pharmacological studies on the actions of the individual components, is referenced in the context of clinical recognition of this combination for these short-term conditions associated with acute or disruptive episodes.

Evidence for use in Proctitis and Other Anorectal Inflammation

Scheriproct Neo was studied for conditions linked to inflammatory or irritative states of the anal region, including proctitis. Research in this area primarily examined the anti-inflammatory contribution of the Prednisolone component, along with regulatory summaries that cite this condition as relevant for study.

The research highlights changes measured during the study period related to localized inflammation. This evidence provides context regarding how patients reported their experience of inflammation and irritation when the preparation was observed in a clinical setting. The use is often described in the context of established research patterns for topical corticosteroids.

Research on Supportive Use in Post-Operative Care

The preparation was evaluated in specific scenarios where supportive relief was studied for, such as in post-operative care following certain anorectal procedures. Studies explored this application by monitoring acute pain, tenderness, and patient-reported comfort levels during the initial recovery phase.

Long-term Follow-up and Duration of Study

Research related to Scheriproct Neo has predominantly examined short-term symptom changes in patients experiencing conditions characterized by fluctuating or episodic manifestations. Because the product is designed for short-term symptomatic support, long-term effects are not fully established in the available literature. There is limited information for long-term outcomes.

Evidence in Specific Patient Populations

The majority of reported evidence and clinical trials was studied for general adult populations experiencing acute symptoms. Data for certain groups remain insufficient. For instance, there is limited information for specific outcomes in older adults, pregnant individuals, or those with significant co-existing medical conditions (comorbidities). Subgroup findings are uncertain or are based on very modest sample sizes.

Research Gaps and What is Still Uncertain

While research provides a framework for understanding the preparation's use, several areas remain uncertain. Comparative evidence is lacking in some contexts, and evidence quality varies across studies. The exact contribution of each component to the overall supportive context in every scenario is still emerging. Ultimately, the research provides context but not individual predictions, and continued studies are needed to address these limitations.

Key Studies & References Health Products Regulatory Authority (HPRA) of Ireland: Scheriproct Neo Product Leaflet (Prednisolone Acetate/Cinchocaine)

Common questions about Scheriproct Neo (FAQ)

Q: Does the ointment work differently than the suppositories?

Official regulatory documents state that both the ointment and the suppositories contain the same active ingredients. The primary difference is the route of application, with the ointment being used for external and internal (via applicator) treatment, and the suppositories being specifically for internal use. This difference in application is linked to how the product is intended to provide local support.

Q: Is there any research on using Scheriproct Neo for anal fissures?

While regulatory sources do not explicitly name anal fissures in the list of indications, the preparation is described in the research context for conditions involving anorectal inflammation. Anal fissures fall into this general class of conditions that are explored in research surrounding the medicine's use.

Q: Do studies show Scheriproct Neo is effective for internal hemorrhoids?

Studies related to the medicine examined patient-reported changes and physical discomfort associated with acute hemorrhoids. The product is physically designed for both internal and external application (via suppository or ointment applicator), indicating the potential for use in both internal and external contexts as described in official information.

Q: Is it normal to feel a slight stinging when applying the cream?

Official safety documentation lists burning sensation and irritation at the site of application as common adverse reactions. These local effects are described as being more frequently observed during the beginning stages of treatment.

Q: Can I use Scheriproct Neo if I have glaucoma?

Official documents indicate the need for ophthalmological evaluation if visual disturbance occurs during use. This evaluation is relevant because visual disturbances may be signs of conditions like glaucoma or cataract, which can be associated with the use of systemic corticosteroids.

Q: Is Scheriproct Neo safe for elderly people?

According to official information, most research evidence was gathered in general adult populations. As a result, specific data and outcomes related to older adults are limited in the available studies.

Q: Can men and women use Scheriproct Neo for the same conditions?

Official documentation describes the use of the medicine for the general adult population. There is no differentiation in eligibility or conditions of use based on sex in the regulatory labeling.

Q: Can I use Scheriproct Neo while breastfeeding? (Informational only)

The official regulatory advice is that treatment during the lactation period is subject to careful review. Furthermore, prolonged use of the preparation while breastfeeding is explicitly forbidden by regulatory constraints.

Q: Can I still drive or operate machinery after using the suppositories?

Official product information does not contain specific warnings or cautions related to the medicine affecting a person's ability to drive or operate machinery.

Q: Is the corticosteroid in Scheriproct Neo strong?

The official labeling describes the corticosteroid component, prednisolone hexanoate, as having a powerful anti-inflammatory action on local application. This powerful action is described as suppressing the biological processes that are associated with swelling and redness at the treated site.

Q: Are there different strengths of Scheriproct Neo available?

Official product composition documents show the preparation is documented with a single set of strengths for the active ingredients in both the ointment and the suppositories. Only one strength is documented in the official product composition records.

Q: What is the main difference in how Scheriproct Neo and a vasoconstrictor work?

The preparation’s pharmacological action is dual: it includes the local anesthetic cinchocaine for pain relief, and the corticosteroid prednisolone, which provides both anti-inflammatory effects and a reduction in capillary dilation (vasoconstriction). This combination is designed to provide concurrent support for both discomfort and swelling.

Q: Can Scheriproct Neo be used for itching not related to hemorrhoids?

Yes, according to official indications, the medicine is listed for the symptomatic relief of pruritus ani (anal itching), in addition to its use for hemorrhoids and proctitis.

Q: What kind of side effects are generally classified as 'rare' for Scheriproct Neo?

Official documentation reports common and uncommon side effects, but some adverse effects associated with systemic corticosteroid use are listed with a frequency of Not known (cannot be estimated from available data). Reported systemic adverse effects listed with a 'Not known' frequency include blurred vision or the potential for conditions such as cataract or glaucoma.

How to Store and Dispose of Scheriproct

Storage requirements for this medicine are dictated by its formulation to ensure the stability of the active ingredients, Prednisolone Acetate and Cinchocaine.

---

Storage Conditions

Formulation	Required Storage Condition
Suppositories	Store in a refrigerator (2 C to 8 C). Shelf life is typically 3 years. If soft, place in cold water to restore consistency.
Ointment	Do not store above 25 C.

---

Child Safety and Disposal

All forms of the medicine must be kept out of the sight and reach of children.

Expired or unused product must not be thrown away in household waste or wastewater. For proper disposal, unused medicine should be returned to a pharmacist for appropriate pharmaceutical waste handling.